Title : Mechanisms of verapamil inhibition of action potential firing in rat intracardiac ganglion neurons - Hogg_1999_J.Pharmacol.Exp.Ther_289_1502 |
Author(s) : Hogg RC , Trequattrini C , Catacuzzeno L , Petris A , Franciolini F , Adams DJ |
Ref : Journal of Pharmacology & Experimental Therapeutics , 289 :1502 , 1999 |
Abstract :
The effects of verapamil and related phenylalkylamines on neuronal excitability were investigated in isolated neurons of rat intracardiac ganglia using whole-cell perforated patch-clamp recording. Verapamil (>/=10 microM) inhibits tonic firing observed in response to depolarizing current pulses at 22 degrees C. The inhibition of discharge activity is not due to block of voltage-dependent Ca2+ channels because firing is not affected by 100 microM Cd2+. The K+ channel inhibitors charybdotoxin (100 nM), 4-aminopyridine (0.5 mM), apamin (30-100 nM), and tetraethylammonium ions (1 mM) also have no effect on firing behavior at 22 degrees C. Verapamil does not antagonize the acetylcholine-induced inhibition of the muscarine-sensitive K+ current (M-current) in rat intracardiac neurons. Verapamil inhibits the delayed outwardly rectifying K+ current with an IC50 value of 11 microM, which is approximately 7-fold more potent than its inhibition of high voltage-activated Ca2+ channel currents. These data suggest that verapamil inhibits tonic firing in rat intracardiac neurons primarily via inhibition of delayed outwardly rectifying K+ current. Verapamil inhibition of action potential firing in intracardiac neurons may contribute, in part, to verapamil-induced tachycardia. |
PubMedSearch : Hogg_1999_J.Pharmacol.Exp.Ther_289_1502 |
PubMedID: 10336545 |
Hogg RC, Trequattrini C, Catacuzzeno L, Petris A, Franciolini F, Adams DJ (1999)
Mechanisms of verapamil inhibition of action potential firing in rat intracardiac ganglion neurons
Journal of Pharmacology & Experimental Therapeutics
289 :1502
Hogg RC, Trequattrini C, Catacuzzeno L, Petris A, Franciolini F, Adams DJ (1999)
Journal of Pharmacology & Experimental Therapeutics
289 :1502